Emma Hamilton-Williams

Professor Emma Hamilton-Williams is a Professorial Research Fellow at the Frazer Institute, University of Queensland. She holds a PhD from the Australian National University and completed postdoctoral training in Germany and at the Scripps Research Institute. Her research focuses on understanding autoimmune mechanisms in type 1 diabetes, particularly involving the gut microbiota and immunotherapy development. She leads the ENDIA cohort study tracking children at risk of type 1 diabetes, investigating environmental drivers like diet and microbiota. Current projects include microbiome-targeted therapies and liposomal nanoparticle-based immunotherapy for disease prevention. She is available for supervision and collaborates extensively with institutions globally.

Education:

• PhD in Biomedical Sciences, Australian National University (2001)
• Bachelor (Honours) of Science (Advanced), Victoria University of Wellington

Research Interests:

Her work spans gut microbiota interactions in type 1 diabetes pathogenesis, prebiotic/probiotic interventions, and antigen-specific immunotherapy using liposomes. She employs proteomics, metabolomics, and metagenomics to study host-microbiota relationships and therapeutic efficacy.

Grants & Funding:

• Current grants include targeting microbial metabolites for diabetes prevention (NHMRC IDEAS) and ENDIA cohort follow-up (JDRF Australia).
• Past funding supported studies on host-microbiota interactions and IL-2 pathways in diabetes.

Advising & Labs:

Current supervision includes projects on microbiome-diet interactions and antigen-specific T-cell responses. Her lab is part of the Frazer Institute, focusing on translational research in immunology and diabetes.